Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

RBC Capital Reiterates Sector Perform on Spruce Biosciences, Maintains $2 Price Target

Author: Benzinga Newsdesk | August 13, 2024 12:29pm
RBC Capital analyst Gregory Renza reiterates Spruce Biosciences (NASDAQ:SPRB) with a Sector Perform and maintains $2 price target.

Posted In: SPRB

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist